Skip over global navigation links

Video conferencing

11/21/2014
The NIH Common Fund High-Risk High-Reward (HRHR) Program seeks to support exceptionally creative investigators who propose bold research ideas of unusally broad impace. The intent of the HRHR symposium is to bring together these outstanding researchers so that they may exchange research results, network with each other, and perhaps forge new collaborations.

Addtional information about the High Risk-High Reward program is available at http://commonfund.nih.gov/highrisk

Air date: 12/16/2014 8:00:00 AM


11/21/2014

The NIH Common Fund High-Risk High-Reward (HRHR) Program seeks to support exceptionally creative investigators who propose bold research ideas of unusually broad impact. The intent of the HRHR symposium is to bring together these outstanding researchers so that they may exchange research results, network with each other, and perhaps forge new collaborations. Addtional information about the High Risk-High Reward program is available at http://commonfund.nih.gov/highrisk/

Addtional information about the High Risk-High Reward program is available at http://commonfund.nih.gov/highrisk/

Air date: 12/15/2014 8:00:00 AM


11/21/2014

The NIH Common Fund High-Risk High-Reward (HRHR) Program seeks to support exceptionally creative investigators who propose bold research ideas of unusually broad impact. The intent of the HRHR symposium is to bring together these outstanding researchers so that they may exchange research results, network with each other, and perhaps forge new collaborations. Additional information about the High-Risk-High Reward program is available at http://commonfund.nih.gov/highrisk/

Air date: 12/17/2014 8:00:00 AM


11/20/2014


This is the first of three workshops sponsored by the NIH Office of the Director on the important topic of reproducibility, the subject of recent editorials in leading scientific journals.

The purpose of these workshops is to educate the NIH intramural research community about what advanced technologies can accomplish and the kinds of reproducibility problems that can arise; provide a cautionary note to scientists who hope to use but are inexperienced with various new modeling techniques; and educate others who are attempting to interpret results in the literature.

We have invited several world-class scientists who will speak about important technologies in cell biology. In addition, we have assembled a panel of editors from five scientific journals covering cell biology to discuss issues with data reproducibility in the scientific literature.

For more information, visit
http://wals.od.nih.gov/reproducibility


Air date: 11/24/2014 8:30:00 AM


11/20/2014

TRACO

Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in development and implementation of many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics.

For more information go to https://ccr.cancer.gov/trainee-resources-courses-workshops-traco

Air date: 11/24/2014 4:00:00 PM


11/20/2014

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multifaceted disorder characterized by extreme fatigue and a host of other symptoms that can worsen after physical or mental activity, but do not improve with rest. In addition to extreme fatigue, people with ME/CFS may also experience:

Widespread muscle and joint pain
Sore throat
Tender lymph nodes in the neck or armpit
Headaches
Sleep problems
Difficulty with short-term memory or concentration
Effects of the illness can range from moderate to debilitating, and can substantially impact everyday functioning. Routine daily activities such as cooking meals, brushing teeth, and caring for children become difficult. Additionally, sensitivity to environmental factors (e.g., noise, light, chemicals) may force many individuals with ME/CFS into seclusion or withdrawal from society.

The onset of ME/CFS symptoms may be sudden—for example, immediately following a viral illness such as the flu—or gradual, with no discernible attachment to a specific event or time. The U.S. Centers for Disease Control and Prevention (CDC) reports over 1 million adults with ME/CFS in the United States, and recent evidence has shown a higher prevalence in females compared to males. Certain racial/ethnic groups have also been found to be at an increased risk for ME/CFS; most notably Native American and African American populations. The economic burden of ME/CFS, including annual health care costs, is estimated to be between $1.9 billion and $7.2 billion.

There are many aspects of ME/CFS that are problematic. First, the underlying mechanisms are unclear. There are differing views as to whether ME/CFS is a central nervous system, metabolic, infectious or post-infectious, cardiovascular, immune system, or other type of disorder. Second, there is little agreement among clinical and research professionals, as well as patient groups, regarding the name of the illness. The name myalgic encephalomyelitis or ME is more commonly used in Europe and Canada, while the name chronic fatigue syndrome or CFS is used more often in the United States and Australia. Yet the acronym ME/CFS is increasingly being used worldwide. Third, no laboratory tests exist for diagnosing ME/CFS, and its diagnosis is one of exclusion. All other illnesses with overlapping symptoms must be ruled out prior to an ME/CFS diagnosis. Fourth, there are no drugs or therapies approved by the U.S. Food and Drug Administration (FDA) to treat ME/CFS. Clinical trials to test drug or therapy effectiveness, and drug development to target the underlying cause, are difficult to conduct because of the unknown causes, varied symptom profile, and lack of concurrence regarding diagnostic criteria. Lastly, medical professionals disagree on many aspects of ME/CFS, including whether the illness is real, and there is no definitive answer about the effectiveness of current therapies (e.g., diet, use of off-label or experimental drugs).

The 2014 Pathways to Prevention Workshop: Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will seek to clarify:

How the research on ME/CFS using multiple case definitions has contributed to the state of the current scientific literature on diagnosis, pathophysiology, treatment, cure, and prevention of ME/CFS

How the measurement outcomes (tools and measures) currently used by researchers of ME/CFS are able to distinguish among those patients diagnosed with ME/CFS, including the sensitivity of the tools and measures to identify subsets of patients according to duration, severity, nature of the illness, onset characteristics, and other categorizations

How the research on treatments or therapies shown to be effective in addressing symptoms of ME/CFS will lead to an understanding of the underlying pathology associated with ME/CFS

How innovative research approaches have provided an understanding of the pathophysiology of ME/CFS, and how this knowledge can be applied to the development of effective and safe treatments.

Initial planning for each Pathways to Prevention workshop, regardless of condition, is coordinated by a Working Group that nominates panelists and speakers, and develops and finalizes questions that frame the workshop. After finalizing the questions, an evidence report is prepared by an Evidence-based Practice Center, through a contract with the Agency for Healthcare Research and Quality (AHRQ). During the 2-day workshop, invited experts discuss the body of evidence, and attendees have opportunities to provide comments during open discussion periods. After weighing evidence from the evidence report, expert presentations, and public comments, an unbiased, independent panel prepares a draft report that identifies research gaps and future research priorities. The draft report is posted on the ODP website, and public comments are accepted for 14 days. The final report is then released approximately 2 weeks later.

For more information go to https://prevention.nih.gov/programs-events/pathways-to-prevention/upcoming-workshops/me-cfs

Air date: 12/9/2014 8:00:00 AM


11/20/2014

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multifaceted disorder characterized by extreme fatigue and a host of other symptoms that can worsen after physical or mental activity, but do not improve with rest. In addition to extreme fatigue, people with ME/CFS may also experience:

Widespread muscle and joint pain
Sore throat
Tender lymph nodes in the neck or armpit
Headaches
Sleep problems
Difficulty with short-term memory or concentration
Effects of the illness can range from moderate to debilitating, and can substantially impact everyday functioning. Routine daily activities such as cooking meals, brushing teeth, and caring for children become difficult. Additionally, sensitivity to environmental factors (e.g., noise, light, chemicals) may force many individuals with ME/CFS into seclusion or withdrawal from society.

The onset of ME/CFS symptoms may be sudden—for example, immediately following a viral illness such as the flu—or gradual, with no discernible attachment to a specific event or time. The U.S. Centers for Disease Control and Prevention (CDC) reports over 1 million adults with ME/CFS in the United States, and recent evidence has shown a higher prevalence in females compared to males. Certain racial/ethnic groups have also been found to be at an increased risk for ME/CFS; most notably Native American and African American populations. The economic burden of ME/CFS, including annual health care costs, is estimated to be between $1.9 billion and $7.2 billion.

There are many aspects of ME/CFS that are problematic. First, the underlying mechanisms are unclear. There are differing views as to whether ME/CFS is a central nervous system, metabolic, infectious or post-infectious, cardiovascular, immune system, or other type of disorder. Second, there is little agreement among clinical and research professionals, as well as patient groups, regarding the name of the illness. The name myalgic encephalomyelitis or ME is more commonly used in Europe and Canada, while the name chronic fatigue syndrome or CFS is used more often in the United States and Australia. Yet the acronym ME/CFS is increasingly being used worldwide. Third, no laboratory tests exist for diagnosing ME/CFS, and its diagnosis is one of exclusion. All other illnesses with overlapping symptoms must be ruled out prior to an ME/CFS diagnosis. Fourth, there are no drugs or therapies approved by the U.S. Food and Drug Administration (FDA) to treat ME/CFS. Clinical trials to test drug or therapy effectiveness, and drug development to target the underlying cause, are difficult to conduct because of the unknown causes, varied symptom profile, and lack of concurrence regarding diagnostic criteria. Lastly, medical professionals disagree on many aspects of ME/CFS, including whether the illness is real, and there is no definitive answer about the effectiveness of current therapies (e.g., diet, use of off-label or experimental drugs).

The 2014 Pathways to Prevention Workshop: Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will seek to clarify:

How the research on ME/CFS using multiple case definitions has contributed to the state of the current scientific literature on diagnosis, pathophysiology, treatment, cure, and prevention of ME/CFS

How the measurement outcomes (tools and measures) currently used by researchers of ME/CFS are able to distinguish among those patients diagnosed with ME/CFS, including the sensitivity of the tools and measures to identify subsets of patients according to duration, severity, nature of the illness, onset characteristics, and other categorizations

How the research on treatments or therapies shown to be effective in addressing symptoms of ME/CFS will lead to an understanding of the underlying pathology associated with ME/CFS

How innovative research approaches have provided an understanding of the pathophysiology of ME/CFS, and how this knowledge can be applied to the development of effective and safe treatments.

Initial planning for each Pathways to Prevention workshop, regardless of condition, is coordinated by a Working Group that nominates panelists and speakers, and develops and finalizes questions that frame the workshop. After finalizing the questions, an evidence report is prepared by an Evidence-based Practice Center, through a contract with the Agency for Healthcare Research and Quality (AHRQ). During the 2-day workshop, invited experts discuss the body of evidence, and attendees have opportunities to provide comments during open discussion periods. After weighing evidence from the evidence report, expert presentations, and public comments, an unbiased, independent panel prepares a draft report that identifies research gaps and future research priorities. The draft report is posted on the ODP website, and public comments are accepted for 14 days. The final report is then released approximately 2 weeks later.

For more information go to https://prevention.nih.gov/programs-events/pathways-to-prevention/upcoming-workshops/me-cfs

Air date: 12/10/2014 8:00:00 AM


11/20/2014

The NICHD Birth Defects Initiative, started in 2000, supports basic scientists and clinicians whose research projects span basic, translational, and clinical approaches to understanding the developmental biology and genetics of structural birth defects. In addition to support by NICHD, the group now includes structural birth defects researchers funded by other NIH Institutes, Centers, and Offices participating in the newly convened Trans-NIH Structural Birth Defects Working Group. Every year at their annual meeting, researchers funded through the Initiative discuss plans and progress of their research, exchange ideas and information, share resources, and foster synergistic collaborations that enhance Initiative goals. A 2014 NIH-funded workshop, Developing an Interdisciplinary Research Agenda for Genetics of Birth Defects, recommended more efforts be devoted to encouraging collaborations between developmental biologists doing basic research in animal models and physician scientists doing clinical research. Toward this end, a special round table discussion, “Establishing successful basic science and clinical collaborations to study structural birth defects” will be held as part of this year’s 10th NICHD Structural Birth Defects Meeting and VideoCast for wider dissemination.

Moderator:
Lorette C. Javois, Ph.D., Developmental Biology and Structural Variation Branch, Eunice Kennedy Shriver National Institute of Child Health & Human Development

Discussants:
Mustafa Khokha, M.D., Associate Professor of Pediatrics and Genetics, Yale School of Medicine Ian Krantz, M.D., Professor of Pediatrics, Children’s Hospital of Philadelphia Simon Rhodes, Ph.D., Dean of the School of Science, Indiana University-Purdue University Indianapolis Liliana Solnica-Krezel, Ph.D., Head, Department of Developmental Biology, Washington University School of Medicine, St. Louis John Wallingford, Ph.D., Assistant Professor, Molecular, Cell and Developmental Biology, University of Texas, Austin

Air date: 12/8/2014 2:10:00 PM


11/20/2014

ACD full board meeting

For more information go to http://acd.od.nih.gov

Air date: 12/12/2014 8:00:00 AM


Up to Top

This page last reviewed: December 14, 2010